Botox for tarsal tunnel syndrome

NewsBot · Feb 9, 2021

Members do not see these Ads. Sign Up.
Efficacy of a single botulinum toxin A injection for distal tarsal tunnel syndrome: A protocol for a randomized, double-blinded trial
Omar Baarini, Beng J Tan, Steven R Edwards
Contemp Clin Trials Commun. 2021 Jan 21;21:100725

Introduction: Distal tarsal tunnel syndrome (DTTS) is characterised by compression of the tibial nerve as it passes underneath the abductor hallucis muscle belly. There is no current consensus on treatment for DTTS. This study was conducted to compare and evaluate the effect of ultrasound-guided botulinum toxin A (BTX-A) versus ultrasound-guided corticosteroid injection (CSI) for the treatment of DTTS.

Methods: This study was a single-centre, randomized, and double-blinded trial. The study protocol was submitted to the local ethics committee board and subsequently registered in a research registry. 88 patients with DTTS were randomly divided into 2 groups according to the treatment received. The patients were evaluated over 12 weeks. Evaluation was via the Foot Health Status Questionnaire (FHSQ). The primary outcome measures were pain and the secondary outcomes were function and the use of oral analgesics. All of the assessments were performed at baseline and at 3, 6, and 12 weeks after treatment.

Results: This is a randomized controlled trial evaluating the efficacy of BTX-A versus CSI in the treatment of DTTS. This study has limited inclusion and exclusion criteria and a well-controlled intervention.

Conclusions: The results of this trial will provide more evidence on which method can better treat DTTS.
Click to expand...

NewsBot The Admin that posts the news.

Botox for compartment syndrome in the leg

Botox use in young adult with 4 x CVA

Botox for Morton's Neuroma

Botox for toe walking

Botox for the treatment of claw/hammer toes

Podiatrists doing Botox and dermal fillers

New Botox & Fillers course for UK Podiatrists

Share This Page